NCT04129411

Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.

Detailed description

Investigators plan to identify patients with small papillary thyroid carcinoma and subject such patients to radiofrequency ablation (RFA) therapy. Following RFA procedure patients will be monitored to study the changes in primary tumor volume, development of lymph node involvement, development of distant metastasis and changes in serum thyroid hormone levels. Investigators will also assess the stability of these changes (need for repeat therapy) and the safety of the RFA procedure.

Conditions

• Papillary Thyroid Cancer
• Papillary Thyroid Microcarcinoma

Interventions

Type	Name	Description
DEVICE	RFA	Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.

Timeline

• Start date: 2020-06-15
• Primary completion: 2024-05-07
• Completion: 2024-05-07
• First posted: 2019-10-16
• Last updated: 2025-05-20
• Results posted: 2025-05-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study